Jaroslav A Hubacek1, Dana Dlouha2, Vera Adamkova3, Lucie Schwarzova4, Vera Lanska5, Richard Ceska4, Martin Satny4, Michal Vrablik4. 1. Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine (IKEM-DEM-LAR), Videnska 1958/9, 140 21, Prague 4, Czech Republic. jahb@ikem.cz. 2. Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine (IKEM-DEM-LAR), Videnska 1958/9, 140 21, Prague 4, Czech Republic. 3. Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 4. 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. 5. Statistical Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Abstract
BACKGROUND: Plasma triglyceride (TG) values are significant predictors of cardiovascular and total mortality. The plasma levels of TGs have an important genetic background. We analyzed whether 32 single nucleotide polymorphisms (SNPs) identified in genome-wide association studies are discriminators of hypertriglyceridemia (HTG) in the Czech population. OBJECTIVES: The objective of this study was to replicate and test the original findings in an independent study and to re-analyze the gene score leading to HTG. METHODS: In total, we analyzed 32 SNPs in 209 patients with plasma TG levels over 10 mmol/L (HTG group) and compared them in a case-control design with 524 treatment-naïve controls (normotriglyceridemic [NTG] group) with plasma TG values below 1.8 mmol/L. RESULTS: Sixteen SNPs were significantly associated with an increased risk of HTG development, with odds ratios (ORs) (95% confidence interval [CI]) varying from 1.40 (1.01-1.95) to 4.69 (3.29-6.68) (rs964184 within the APOA5 gene). Both unweighted (sum of the risk alleles) and weighted gene scores (WGS) (log of the achieved ORs per individual genotype) were calculated, and both gene scores were significantly different between groups. The mean score of the risk alleles was significantly increased in the HTG group compared to the NTG group (18.5 ± 2.5 vs. 15.7 ± 2.3, respectively; P < 0.00001). Subjects with a WGS over 9 were significantly more common in the HTG group (44.5%) than in the NTG group, in which such a high score was observed in only 4.7% of subjects (OR 16.3, 95% CI 10.0-36.7; P < 0.0000001). CONCLUSIONS: An increased number of risk genetic variants, calculated both in a weighted or unweighted manner, significantly discriminates between the subjects with HTG and controls. Population-specific sets of SNPs included into the gene score seem to yield better discrimination power.
BACKGROUND: Plasma triglyceride (TG) values are significant predictors of cardiovascular and total mortality. The plasma levels of TGs have an important genetic background. We analyzed whether 32 single nucleotide polymorphisms (SNPs) identified in genome-wide association studies are discriminators of hypertriglyceridemia (HTG) in the Czech population. OBJECTIVES: The objective of this study was to replicate and test the original findings in an independent study and to re-analyze the gene score leading to HTG. METHODS: In total, we analyzed 32 SNPs in 209 patients with plasma TG levels over 10 mmol/L (HTG group) and compared them in a case-control design with 524 treatment-naïve controls (normotriglyceridemic [NTG] group) with plasma TG values below 1.8 mmol/L. RESULTS: Sixteen SNPs were significantly associated with an increased risk of HTG development, with odds ratios (ORs) (95% confidence interval [CI]) varying from 1.40 (1.01-1.95) to 4.69 (3.29-6.68) (rs964184 within the APOA5 gene). Both unweighted (sum of the risk alleles) and weighted gene scores (WGS) (log of the achieved ORs per individual genotype) were calculated, and both gene scores were significantly different between groups. The mean score of the risk alleles was significantly increased in the HTG group compared to the NTG group (18.5 ± 2.5 vs. 15.7 ± 2.3, respectively; P < 0.00001). Subjects with a WGS over 9 were significantly more common in the HTG group (44.5%) than in the NTG group, in which such a high score was observed in only 4.7% of subjects (OR 16.3, 95% CI 10.0-36.7; P < 0.0000001). CONCLUSIONS: An increased number of risk genetic variants, calculated both in a weighted or unweighted manner, significantly discriminates between the subjects with HTG and controls. Population-specific sets of SNPs included into the gene score seem to yield better discrimination power.
Authors: Jacqueline S Dron; Jian Wang; Henian Cao; Adam D McIntyre; Michael A Iacocca; Jyler R Menard; Irina Movsesyan; Mary J Malloy; Clive R Pullinger; John P Kane; Robert A Hegele Journal: J Clin Lipidol Date: 2018-10-24 Impact factor: 4.766
Authors: Nadeem Sarwar; Manjinder S Sandhu; Sally L Ricketts; Adam S Butterworth; Emanuele Di Angelantonio; S Matthijs Boekholdt; Willem Ouwehand; Hugh Watkins; Nilesh J Samani; Danish Saleheen; Debbie Lawlor; Muredach P Reilly; Aroon D Hingorani; Philippa J Talmud; John Danesh Journal: Lancet Date: 2010-05-08 Impact factor: 79.321
Authors: Philippa J Talmud; Jackie A Cooper; Richard W Morris; Frank Dudbridge; Tina Shah; Jorgen Engmann; Caroline Dale; Jon White; Stela McLachlan; Delilah Zabaneh; Andrew Wong; Ken K Ong; Tom Gaunt; Michael V Holmes; Debbie A Lawlor; Marcus Richards; Rebecca Hardy; Diana Kuh; Nicholas Wareham; Claudia Langenberg; Yoav Ben-Shlomo; S Goya Wannamethee; Mark W J Strachan; Meena Kumari; John C Whittaker; Fotios Drenos; Mika Kivimaki; Aroon D Hingorani; Jacqueline F Price; Steve E Humphries Journal: Diabetes Date: 2014-12-04 Impact factor: 9.461